VIP (Vasoactive Intestinal Peptide)

At a glance

Standard Protocol

Alternative Titration 1: 8-Week Protocol

Alternative Titration 2: 3-Month Protocol

Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (VIP Receptors); route Subcutaneous; timing Morning or early afternoon. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.

• Rapid blood pressure drop (hypotension): the primary and most serious adverse effect; VIP-mediated smooth muscle relaxation in systemic and pulmonary vasculature can produce a sudden, significant blood pressure decrease within minutes of injection, particularly if administered quickly; the protocol instruction to inject "very slowly" is the critical mitigating intervention.
• Dizziness and lightheadedness: secondary to acute vasodilation and blood pressure drop; patients should be seated or supine during administration.
• Flushing and sensation of warmth: vasodilation-mediated; particularly facial flushing; onset within minutes; typically transient.
• Rapid heartbeat (tachycardia): reflex compensatory heart rate increase in response to vasodilation-induced blood pressure drop; transient.
• Headache: vasodilation-related; common in subjects sensitive to vasodilatory peptides.
• Nausea: gastrointestinal smooth muscle relaxation; VIP is an intestinal secretagogue; dose-related.
• Diarrhea and watery stools: VIP stimulates intestinal chloride secretion and fluid secretion in the gut; at higher doses, this is a pharmacological consequence of the mechanism (VIPoma syndrome, characterized by profuse watery diarrhea, is the extreme pathological version of this effect).
• Transient nasal congestion: more commonly associated with intranasal route; mild.
• Increased susceptibility to intracellular pathogens (theoretical): VIP's immunomodulatory tolerance programming that promotes T-regulatory cells and suppresses Th1 responses could, at sustained high doses, impair cell-mediated immunity against intracellular pathogens (mycobacteria, Listeria, viruses).
• Syncope: in subjects with baseline hypotension or cardiovascular instability; the most serious acute risk; requires lying down, fluid intake, and monitoring.

• Hypotension (low blood pressure): VIP is one of the most potent endogenous vasodilators; administering it in a subject with baseline low blood pressure risks dangerous acute hypotension, syncope, and cardiovascular instability.
• Use before upstream CIRS inflammatory markers are normalized: per the Shoemaker Protocol, VIP is the final intervention step; using VIP in subjects with unresolved elevated MMP-9, TGF-β1, or C4a will produce insufficient therapeutic benefit and may worsen symptoms.
• Active ongoing mold or biotoxin exposure: VIP will not maintain therapeutic effect if the biotoxin source has not been eliminated (e.g., still living in a water-damaged building).
• Hypersensitivity to VIP or peptide excipients.
• Concurrent use of other vasodilatory agents (e.g., PDE5 inhibitors, nitrates, alpha-blockers): additive vasodilation and hypotension risk.
• Subjects on antihypertensive medications: the combined vasodilatory effect may reduce blood pressure below safe thresholds.
• VIPoma (VIP-secreting tumor): endogenous VIP is already pathologically elevated; exogenous administration is absolutely contraindicated.
• Severe cardiovascular disease with labile blood pressure or recent myocardial infarction.
• Pregnancy: VIP plays a role in uterine tone regulation; exogenous VIP administration during pregnancy is not established as safe.
• Pediatric use: safety not established.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=VIP+%28Vasoactive+Intestinal+Peptide%29